Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03804840 · ClinicalTrials.gov registry record · Early Phase 1

Developing a Mobile Method to Measure THC-induced Impairment

A Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application, sponsored by University of Chicago.

Completed
Registry status
Early Phase 1
Development phase
72
Enrollment target
1
Study location

NCT03804840: Completed Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application, sponsored by University of Chicago.

NCT03804840 is a Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application that has completed, run by University of Chicago. The registered enrollment target is 72 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03804840, a Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Early Phase 1
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

Marijuana use, for both recreational and therapeutic purposes, is becoming increasingly common as states remove restrictions on use. The increased use raises new concern about the safety of this drug, including its ability to impair basic cognitive and psychomotor tasks, and whether the users are aware of their impairment. We propose to design a simple performance test that users can use in the field, using a cell phone, to assess their level of impairment relative to their own drug-free state. In this preliminary study, we will compare participants' simple task performance after a known dose of delta-9-tetrahydrocannabinol (THC), or placebo, administered under double-blind conditions. In our app the participants will be asked to gauge their own perceived level of impairment (as determined by self-ratings and judgments of impairment) as well as their actual impairment (as gauged by the app), providing important feedback and training about their ability to detect impairment.

Primary Outcome

In this reaction time task, the user is asked to shake the device in response to a visual clue on the device's screen. The user makes three attempts, in which he or she must shake or move the device with an acceleration that is greater than the value of the thresholdAcceleration property within the given time. The task finishes when the user successfully completes the attempts as instructed in the task. Data collected by this task is in the form of ORKReactionTimeResult objects. Each of these ob

Interventions

  • DRUG Placebo
  • DRUG Dronabinol

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2017-03-01
Est. Completion 2018-12-01
Phase Early Phase 1
University of Chicago

796 total trials

What the finished NCT03804840 record still lists

NCT03804840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher).

The record links to 1 condition, with Measuring THC-induced Cognitive Impairment Using a Mobile Application appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03804840 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT03804840 about?

NCT03804840 is a clinical study titled "Developing a Mobile Method to Measure THC-induced Impairment". Marijuana use, for both recreational and therapeutic purposes, is becoming increasingly common as states remove restrictions on use. The increased use raises new concern about the safety of this drug, including its ability to impair basic cognitive and psychomotor tasks, and whether the users are aw...

What is the current status of trial NCT03804840?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2017-03-01. Estimated completion is 2018-12-01.

What conditions does trial NCT03804840 study?

This clinical trial studies the following conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application.

What interventions are being tested in trial NCT03804840?

The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).

Who is sponsoring clinical trial NCT03804840?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03804840 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03804840's enrollment target sits among peer trials

72 319th of 2000 higher than 1,674 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03804840, the US trial registry maintained by the National Library of Medicine. NCT03804840 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.